We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 22, 2021

Mirvetuximab Soravtansine vs Chemotherapy in Patients With Platinum-Resistant Ovarian Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Phase III, Randomized Trial of Mirvetuximab Soravtansine Versus Chemotherapy in Patients With Platinum-Resistant Ovarian Cancer: Primary Analysis of FORWARD I
Ann. Oncol 2021 Mar 02;[EPub Ahead of Print], KN Moore, AM Oza, N Colombo, A Oaknin, G Scambia, D Lorusso, GE Konecny, S Banerjee, CG Murphy, JL Tanyi, H Hirte, JA Konner, PC Lim, M Prasad-Hayes, BJ Monk, P Pautier, J Wang, A Berkenblit, I Vergote, MJ Birrer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading